MAIA Biotechnology Announces Presentation of Phase 2 THIO-101 Clinical Trial Results at BIO International Convention 2025

Reuters

2025/06/10

MAIA Biotechnology Announces Presentation of Phase 2 THIO-101 Clinical Trial Results at BIO International Convention 2025

Maia Biotechnology Inc., a clinical-stage biopharmaceutical company, has announced its participation in the upcoming BIO International Convention 2025, scheduled for June 16-19 in Boston, Massachusetts. During the event, Chairman and CEO Vlad Vitoc, MD, MBA, will present the latest findings from the company's THIO-101 Phase 2 clinical trial on June 18 at 11:30 AM EDT. The trial evaluates ateganosine (THIO), a small molecule telomere-targeting anticancer agent, sequenced with the immune checkpoint inhibitor cemiplimab (Libtayo®) in advanced non-small cell lung cancer (NSCLC). The results of the trial, which aim to be the first completed clinical study of a telomere-targeting agent in cancer treatment, have not yet been presented and are expected to be disclosed during this session. The company has also announced the expansion of the trial to further assess the efficacy of the treatment in third-line NSCLC patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250610821026) on June 10, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2542036314"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542036314\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2542036314?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-10 20:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542036314","market":"us","top_or_hot":-1,"title":"MAIA Biotechnology Announces Presentation of Phase 2 THIO-101 Clinical Trial Results at BIO International Convention 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MAIA Biotechnology Announces Presentation of Phase 2 THIO-101 Clinical Trial Results at BIO International Convention 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Maia Biotechnology Inc., a clinical-stage biopharmaceutical company, has announced its participation in the upcoming BIO International Convention 2025, scheduled for June 16-19 in Boston, Massachusetts. During the event, Chairman and CEO Vlad Vitoc, MD, MBA, will present the latest findings from the company's THIO-101 Phase 2 clinical trial on June 18 at 11:30 AM EDT. The trial evaluates ateganosine (THIO), a small molecule telomere-targeting anticancer agent, sequenced with the immune checkpoint inhibitor cemiplimab (Libtayo®) in advanced non-small cell lung cancer (NSCLC). The results of the trial, which aim to be the first completed clinical study of a telomere-targeting agent in cancer treatment, have not yet been presented and are expected to be disclosed during this session. The company has also announced the expansion of the trial to further assess the efficacy of the treatment in third-line NSCLC patients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250610821026) on June 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MAIA Biotechnology Announces Presentation of Phase 2 THIO-101 Clinical Trial Results at BIO International Convention 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMAIA Biotechnology Announces Presentation of Phase 2 THIO-101 Clinical Trial Results at BIO International Convention 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-10 20:46</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MAIA Biotechnology Announces Presentation of Phase 2 THIO-101 Clinical Trial Results at BIO International Convention 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Maia Biotechnology Inc., a clinical-stage biopharmaceutical company, has announced its participation in the upcoming BIO International Convention 2025, scheduled for June 16-19 in Boston, Massachusetts. During the event, Chairman and CEO Vlad Vitoc, MD, MBA, will present the latest findings from the company's THIO-101 Phase 2 clinical trial on June 18 at 11:30 AM EDT. The trial evaluates ateganosine (THIO), a small molecule telomere-targeting anticancer agent, sequenced with the immune checkpoint inhibitor cemiplimab (Libtayo®) in advanced non-small cell lung cancer (NSCLC). The results of the trial, which aim to be the first completed clinical study of a telomere-targeting agent in cancer treatment, have not yet been presented and are expected to be disclosed during this session. The company has also announced the expansion of the trial to further assess the efficacy of the treatment in third-line NSCLC patients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250610821026) on June 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nNDL6XZ6Dr:1","article_id":"2542036314","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542036314","pubTimestamp":1749559579,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Maia Biotechnology Inc., a clinical-stage biopharmaceutical company, has announced its participation in the upcoming BIO International Convention 2025, scheduled for June 16-19 in Boston, Massachusetts. During the event, Chairman and CEO Vlad Vitoc, MD, MBA, will present the latest findings from the company's THIO-101 Phase 2 clinical trial on June 18 at 11:30 AM EDT. The trial evaluates ateganosine , a small molecule telomere-targeting anticancer agent, sequenced with the immune checkpoint inhibitor cemiplimab  in advanced non-small cell lung cancer . The results of the trial, which aim to be the first completed clinical study of a telomere-targeting agent in cancer treatment, have not yet been presented and are expected to be disclosed during this session. The company has also announced the expansion of the trial to further assess the efficacy of the treatment in third-line NSCLC patients.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MAIA":"MAIA Biotechnology Inc."},"translate_title":"MAIA Biotechnology宣布在2025年BIO国际大会上展示2期THIO-101临床试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MAIA":0.9},"content_text":"MAIA Biotechnology Announces Presentation of Phase 2 THIO-101 Clinical Trial Results at BIO International Convention 2025\n    \n\n        Maia Biotechnology Inc., a clinical-stage biopharmaceutical company, has announced its participation in the upcoming BIO International Convention 2025, scheduled for June 16-19 in Boston, Massachusetts. During the event, Chairman and CEO Vlad Vitoc, MD, MBA, will present the latest findings from the company's THIO-101 Phase 2 clinical trial on June 18 at 11:30 AM EDT. The trial evaluates ateganosine (THIO), a small molecule telomere-targeting anticancer agent, sequenced with the immune checkpoint inhibitor cemiplimab (Libtayo®) in advanced non-small cell lung cancer (NSCLC). The results of the trial, which aim to be the first completed clinical study of a telomere-targeting agent in cancer treatment, have not yet been presented and are expected to be disclosed during this session. The company has also announced the expansion of the trial to further assess the efficacy of the treatment in third-line NSCLC patients.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250610821026) on June 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}